Pros and cons of docetaxel used to treat metastatic hormone-sensitive prostate cancer: The cons

被引：0
|
作者：
Suzuki, Kazuhiro [1 ]
机构：
[1] Gunma Univ, Grad Sch Med, Dept Urol, Maebashi, Gunma, Japan
来源：
ANNALS OF ONCOLOGY | 2016年 / 27卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
WS-1-2
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Management of Metastatic Hormone-Sensitive Prostate Cancer
    Brandon Bernard
    Christopher J. Sweeney
    Current Urology Reports, 2015, 16
  • [22] Management of Hormone-Sensitive Metastatic Prostate Cancer
    Agarwal, Neeraj
    Hussain, Maha
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2013, 27 (06) : 1221 - +
  • [23] Update on Metastatic Hormone-Sensitive Prostate Cancer
    Chi, Kim N.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2022, 20 (05) : 277 - 280
  • [24] Efficacy of bi-weekly docetaxel in hormone-sensitive metastatic prostate cancer (mHSPC).
    Lombana Quinonez, Milton Alberto
    Milena Torres, Ana
    Gonzalez, Guido
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [25] Indirect comparison of abiraterone acetate and docetaxel for treatment of metastatic "hormone-sensitive" prostate cancer
    Feyerabend, S.
    Saad, F.
    Li, T.
    Ito, T.
    Diels, J.
    Van Sanden, S.
    De Porre, P.
    Roiz, J.
    Abogunrin, S.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Abiraterone vs. docetaxel for metastatic hormone-sensitive prostate cancer: A microsimulation model
    Hird, Amanda E.
    Magee, Diana E.
    Cheung, Douglas C.
    Matta, Rano
    Kulkarni, Girish S.
    Nam, Robert K.
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2020, 14 (09): : E418 - E427
  • [27] Pros and Cons of Focal Therapy for Localised Prostate Cancer
    Mearini, Luigi
    Porena, Massimo
    PROSTATE CANCER, 2011, 2011
  • [28] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Michael T. Schweizer
    Roman Gulati
    Elahe A. Mostaghel
    Peter S. Nelson
    R. Bruce Montgomery
    Evan Y. Yu
    Heather H. Cheng
    Medical Oncology, 2016, 33
  • [29] Docetaxel-related toxicity in metastatic hormone-sensitive and metastatic castration-resistant prostate cancer
    Schweizer, Michael T.
    Gulati, Roman
    Mostaghel, Elahe A.
    Nelson, Peter S.
    Montgomery, R. Bruce
    Yu, Evan Y.
    Cheng, Heather H.
    MEDICAL ONCOLOGY, 2016, 33 (07)
  • [30] TITAN study: evaluation of apalutamide in patients with metastatic hormone-sensitive prostate cancer - Treatment of metastatic hormone-sensitive prostate cancer (mHSPC)
    Merseburger, Axel S.
    Suttmann, Henrik
    AKTUELLE UROLOGIE, 2021, 52 (02) : 155 - 160
12345